Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population

Journal of Clinical Pharmacology

Volumn 45, Issue 8, 2005, Pages 895-900

  Vercaigne, Lavern M ^a,b   Collins, David M ^a   Penner, S Brian ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Renal Program   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Dialysis; Dosing; Erythropoietin; Intravenous; Sub cutaneoushemo

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REGIMEN; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 23044449036     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005278808     Document Type: Article

References (21)

1. Manitoba Renal Program. Health Sciences Centre, Winnipeg, Manitoba, Canada, 2003.
2. Canadian Society of Nephrology. Update on pure red cell aplasia (PRCA) associated with erythropoietic therapies, 2003.
3. Albitar S, Meulders Q, Hammoud H, Soutif C, Bouvier P, Pollini J. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant. 1995;10(Suppl 6):40-43.
4. Balkovetz DF, Frazier C, Sanders PW. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit. Nephrol Dial Transplant. 1998;13:2979-2980.
5. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-1416.
6. Bommer J, Response to EPO therapy. Przegl Lek. 1992;49:36-37.
7. Bommer J, Barth HP, Zeier M, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol. 1991;88:136-143.
8. Granolleras C, Branger B, Deschodt G, Shaldon S, Nonnast-Daniel B, Pollok M. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients. Contrib Nephrol. 1990;82:49-54.
9. Paganini EP, Eschbach JW, Lazarus JM, et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis. 1995;26:331-340.
10. Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration. Nephron. 1991;57:485-486.
11. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439-446.
12. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients: IV and SC erythropoietin. Eur J Clin Pharmacol. 1996;50:171-177.
13. Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin Nephrol. 1994;41:297-302.
14. De Schoenmakere G, Lameire N, Dhondt A, et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant. 1998;13:1770-1775.
15. Jacobs C, Horl WH, Macdougall IC, et al. European best practice guidelines 9-13: anaemia management. Nephrol Dial Transplant. 2000;15(Suppl 4):33-42.
16. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis. 2001;37:E36.
17. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339:578-583.
18. Macdougall IC. Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant. 2002;17:2047-2051.
19. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19:141-149.
20. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63-72.
21. Petersen J, Kang MS, Yeh I. The site of injection affects erythropoietin levels during dialysis. Asaio J. 1996;42:263-265.